Home > Resources > Blogs

Back to resources

Blogs

Blog

ICH M3 R2 approaches for exploratory studies

Anne-Fleur Verhaar, MD
Blog

Strong data for start-up and scale-up biotech investments

Ari Aminetzah, MBA
Blog

Informed Consent Form for research: ICF in clinical trials

Tessa Aminetzah
Blog

Antibody fragments

Bob Wesdorp
Blog

Nanobody vs antibody

Bob Wesdorp
Blog

Regulation EU No 536 2014

Tessa Aminetzah
Blog

Guide on monoclonal antibody naming

Bob Wesdorp
Blog

SPECT vs PET in drug development

Maarten Brom, PhD
Blog

5 differences between Phase 1 0 in drug development

Bob Wesdorp
Blog

What are the 2 methods for labelling antibodies?

Maarten Brom, PhD
Blog

How long is Phase 0 in clinical trials?

Bob Wesdorp
Blog

The preclinical work before your Phase 0 imaging study

Maarten Brom, PhD
Blog

Labeling of antibodies and antibody derivatives for molecular imaging

Maarten Brom, PhD
Blog

Benefits of including Phase 0 imaging study in your fundraising pitch

Ari Aminetzah, MBA
Blog

How to select a patient population for your Phase 0 trial

Milou Noltes, MD, PhD
Blog

Why you don’t need imaging to apply microdosing

Maarten Brom, PhD
Blog

Molecular imaging in gene therapy

Prof. G.M. van Dam, MD, PhD
Blog

Molecular imaging of CAR-T cell therapy

Milou Noltes, MD, PhD
Blog

The value of Phase 0 imaging data to your IND application

Maarten Brom, PhD
Blog

How a Phase 0 imaging study can propel your radiopharmaceutical development

Maarten Brom, PhD
Blog

How to get your first-in-human trial approved in The Netherlands

Prof. Go van Dam, MD, PhD
Blog

Microdosing with and without molecular imaging

Milou Noltes, MD, PhD
Blog

Does a Phase 0 study influence your Phase 1 trial?

Maarten Brom, PhD
Blog

Molecular imaging in anti-diabetic drug development

Maarten Brom, PhD
Blog

Why and how to standardize quantified PET scans in your trial

Milou Noltes, MD, PhD
Blog

Molecular imaging of cancer vaccines

Maarten Brom, PhD
Blog

How your Phase 2 or 3 trial can benefit from molecular imaging

Maarten Brom, PhD
Blog

An introduction to optoacoustic imaging in drug development

Milou Noltes, MD, PhD
Blog

The FDA Fast Track program: the ins and outs

Prof. G.M. van Dam, MD, PhD
Blog

Molecular imaging as a blueprint for patient stratification

Prof. G.M. van Dam, MD, PhD
Blog

Who are involved in molecular imaging clinical trials?

Maarten Brom, PhD
Blog

Why you don’t need a GMP-compound to start your first-in-human study

Maarten Brom, PhD
Blog

Fast clinical translation of your therapeutic compound: A stepwise approach

Maarten Brom, PhD
Blog

What quality grade labeled compounds do you need in your trials?

Maarten Brom, PhD
Blog

What is the optimal label to trace your compound?

Maarten Brom, PhD
Blog

How to design your first-in-human study: patient and tracer selection

Prof. Go van Dam, MD, PhD
Blog

Types of nuclear medicine imaging techniques

Maarten Brom, PhD
Blog

Four reasons to conduct your clinical trial in The Netherlands

Prof. G.M. van Dam, MD, PhD
Blog

Three Nuclear Imaging Strategies for Anti-inflammatory Drug Development

Maarten Brom, PhD
Blog

How to Use a Multimodal Imaging Approach in Clinical Trials

Maarten Brom, PhD
Blog

Gerard: ‘We both knew that what we were about to do could change the world’

Tessa Aminetzah
Blog

The latest developments in fluorescence imaging

Pieter Steinkamp, MD, PhD cand.
Blog

Radiopharmaceuticals are on the rise as drug developers realize enormous potential

Prof. G.M. van Dam, MD, PhD
Blog

How to determine clinical endpoints for fluorescence-guided surgery

Prof. G.M. van Dam, MD, PhD
Blog

How does cardiovascular imaging work?

Prof. G.M. van Dam, MD, PhD
Blog

How to generate in-human data on antibodies with microdosing

Pieter Steinkamp, MD, PhD cand.
Blog

Hitting the R&D sweet spot with fast in-human studies

Prof. G.M. van Dam, MD, PhD
Blog

5 must read articles that changed the molecular imaging space

Prof. G.M. van Dam, MD, PhD
Blog

What are clinical molecular imaging studies?

Pieter Steinkamp, MD, PhD cand.
Blog

The use of nuclear and optical molecular imaging in drug development

Prof. G.M. van Dam, MD, PhD
Blog

How to use in-human data as an investment strategy

Ari Aminetzah, MBA, PhD cand.
Blog

How to transform your compound into in-human data in five steps

Prof. G.M. van Dam, MD, PhD
Blog

How to achieve a broad implementation of molecular imaging in drug development

Maarten Brom, PhD
Blog

How molecular imaging helps predict immunotherapy response

Maarten Brom, PhD
Blog

In-Human Microdosing

Prof G.M. Van Dam, MD, PhD